HRSA’s release of the revised 340B Rebate Pilot Program on July 31, 2026, is another indication that the administration recognizes effective drug discount management is increasingly dependent on claims-and encounter-level data.
While the revised pilot applies only to manufacturers with drugs selected under the 2026 and 2027 Medicare Drug Price Negotiation Program, its implications extend well beyond the pilot itself. It signals a growing willingness to move away from an opaque, fragmented, package-based, on-invoice model toward a utilization-based rebate model, where discounts are provided directly to healthcare providers based on actual utilization. This approach brings the 340B program into closer alignment with other unit-based discount programs such as Medicare’s Maximum Fair Price (MFP) and Medicaid’s Drug Rebate program (MDRP).
For manufacturers eligible for the pilot, the timeline is compressed. Those that wish to participate must submit their rebate plans to HRSA by August 24, 2026. HRSA expects to make decisions on submitted plans by September 24, 2026, with approved plans going live January 1, 2027, or later.
But manufacturers that are not eligible to participate in this initial round of 340B rebate pilots should not view themselves as being left behind. Instead, they should view it as an opportunity to evaluate whether their current operating model is prepared for where drug discount management may be heading.
The more strategic question for every manufacturer is: What can we do today to prepare for the next phase of drug discount management?
More Than a Compliance Exercise
The revised guidance introduces several notable changes, including enhanced data privacy requirements, mandatory unit-level rebate payments, expanded pharmacy and medical claims data requirements, and expectations around covered entity support.
Taken together, these updates reinforce an important reality: successfully administering a rebate model requires far more than processing payments. Manufacturers need the ability to:
- Securely collect and validate claims data
- Calculate rebates accurately
- Facilitate payments within required timeframes
- Manage disputes and exceptions
- Maintain complete audit documentation
As manufacturers move forward, whether by participating in the rebate model pilot or in taking the preparatory step of collecting claims-and encounter-level data, these capabilities are quickly becoming core operational requirements for manufacturers and their business partners.
The Challenge Isn’t One Program: It’s Managing Them Together
The 340B rebate pilot doesn’t exist in isolation.
Manufacturers are simultaneously managing 340B, MFP, MDRP, commercial rebates, and other drug discount programs. Each has its own requirements, timelines, and data sources, yet all ultimately affect gross-to-net performance.
Managing these programs independently creates fragmented data, duplicate processes, and limited visibility across the organization. As new pricing models emerge, that complexity will only continue to grow.
Rather than adding another standalone workflow, manufacturers have an opportunity to take a more approach to drug discount management. One that improves visibility, increases operational efficiency, and helps coordinate activity across programs.
Preparing for What’s Next
For manufacturers choosing to participate in the pilot, the immediate priority is readiness, including evaluating whether previously submitted plans need to be updated before the August 24 submission deadline. This includes preparing claims intake and validation, rebate calculations, payment operations, exception management, data governance, security, covered entity support, and cross-program coordination.
For manufacturers not included in the initial pilot, this is still an important opportunity to assess current operations and overall drug discount management readiness. As claims- and encounter-based rebate models continue to evolve, building connected, scalable, and flexible capabilities today can help organizations adapt more quickly to future regulatory changes and operational requirements.
Manufacturers that begin preparing now will be better positioned to realize operational benefits today while building the foundation for long-term success in the post-pilot environment.
How Model N Can Help
Truzo by Model N helps manufacturers with a connected, end-to-end workflow spanning claims ingestion, eligibility validation, rebate calculation, payment facilitation, reconciliation, exception management, reporting, and audit support.
By connecting 340B data with MFP, Medicaid, and commercial rebates, as well as other drug discount programs, Truzo delivers the claims-level visibility and cross-program coordination manufacturers need to identify potential duplicate discounts, streamline operations, support compliance, and make more informed gross-to-net decisions.
HRSA’s revised 340B Rebate Pilot is another step forward, but it isn’t the only step, but it is only one part of a broader transformation in drug discount management. Manufacturers that invest in connected, claims-driven capabilities today will be better positioned to adapt as rebate models and regulatory requirements continue to evolve.
Let’s Connect
Whether you’re submitting an August 24 plan or preparing for the next phase of drug discount management, Model N is here to ensure you’re ready.
